“✔베스트토토먹튀없음【평생베스트.com】베스트토토안전확인✔”的搜索结果，显示 111-120 项，共有 7492 项

1. 皮肤科- 临床试验- 妙佑医疗国际

   ... best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma. A Study to Evaluate Perceptions of Midline ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic leukemia that ...

3. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma. Prospective Use of Philips iSuite for ...

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This phase I/II trial studies the side effects and best dose of romidepsin and lenalidomide when combined with rituximab and to see how well this ...

5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... best overall response rate (BORR) of combined ramucirumab (RAM) plus paclitaxel (+/- pembrolizumab) following induction pembrolizumab (PEM) in patients with ...

6. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This phase Ib trial studies the side effects and best dose of a vaccine called H2NVAC before surgery in treating patients with HER2 expressing ductal carcinoma ...

7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... best overall response rate (BORR) of combined ramucirumab (RAM) plus paclitaxel (+/- pembrolizumab) following induction pembrolizumab (PEM) in patients with ...

8. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... best overall response rate (BORR) of combined ramucirumab (RAM) plus paclitaxel (+/- pembrolizumab) following induction pembrolizumab (PEM) in patients with ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... best overall response rate (BORR) of combined ramucirumab (RAM) plus paclitaxel (+/- pembrolizumab) following induction pembrolizumab (PEM) in patients with ...

10. 肾病和高血压- 临床试验- 妙佑医疗国际

    This study is being done to gather information regarding your health in relation to your composite tissue transplant. We would like to use your medical ...